focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
I agree the gearing ratio does look high. Also the current ratio/cash balance suggests they do not have much reserves in case of difficulties. Although I am sure £500,000 loan from NEW should help. Everyone seems to be using amazon for cloud storage at the moment. Even company house!
Here is Big sofa's twitter account. https://twitter.com/thebigsofa
In case anyone has not realised The Insight Exchange Limited trades as the Big sofa company. https://www.endole.co.uk/company/05632680/the-insight-exchange-limited Here are its accounts please check them out: https://companycheck.co.uk/company/OC344669/THE-INSIGHT-EXCHANGE-PARTNERSHIP-LLP/financial-accounts It has 5 years of Pre Tax Profit being positive. Very high Return on Capital Employed and Return on Net Assets Employed. The addition of extra capital from NEW should allow this company to rapidly grow. I think this would be a good company to RTO into NEW and should lead to a transformation of the prospects for NEW. What does everyone else think of The big sofa/Insight Exchange financials?
Hi all, This is good news. According to Bloomberg "The Insight Exchange Partnership LLP", trades as Big Sofa. http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=302752411 https://beta.companieshouse.gov.uk/company/OC344669/filing-history Full accounts show a profit in 2013 £667,650 and in 2014 £299,082. (No accounts for 2015 yet unfortunately) So its profitable in a fast growing sector. Looking to expand. Sounds good for the RTO.
FINNCAP 21/03/16 09:18 Bioventrix*: Interim results (CORP) Bioventix has reported interim results to 31 December 2015. Revenues rose 23% to £2.37m, driven in part by the on-going roll-out of the vitamin D test utilising its antibody, estimated to have accounted for c.80% of the incremental growth, but underpinned also by good growth of c.7% in the remaining antibody portfolio. With operating costs broadly flat, EBITDA margins rose 510bps to 72.2% which, in turn, resulted in a 30% increase in EPS. In line with indicated comments at prelims, an interim dividend of 16.5p was declared – a 50% increase. Net cash at period-end was £4.6m, up from £4.1m at 30 June and after the £1.28m final dividend payment. We have raised our target price to 1250p from 1040p, at which level the shares would trade on a FY16 PER and EV/EBITDA of 21.4x and 16.0x, respectively; representing 25% and 15% discounts to respective Abcam multiples and considered appropriate given the more concentrated product portfolio. Analyst: Mark Brewer
I think it is one of the big shareholders selling down abit of their position in stages. It allows us smaller shareholders to purchase the shares at a discount to fair value :)
Someone sold £~950,000 worth of shares today. Should be a holding RNS shortly. I think after the interim statement and the positive outlook it is worth holding for the longterm. I will not be selling.
Combination therapy for HER2 solid breast tumours causes them to disappear in 11 days accoriding to a report in European Breast Cancer Conference in Amsterdam. This could lead to a big increase in Tyverb sales. Which have been quite small so far. http://www.telegraph.co.uk/news/health/news/12190094/Breast-cancer-tumours-killed-in-11-days-with-staggering-new-therapy.html
Paul Scott of stockopedia fame is now buying Zytronics. So he can also see good value in this share. A reasonably priced GARP stock. http://www.stockopedia.com/content/small-cap-value-report-19-jan-2016-dotd-xlm-stm-frp-118430/
http://www.iii.co.uk/articles/288002/top-10-quality-aim-shares-2016? PE of 15, and once the 9M of cash is removed from Market cap (As Peter Lynch suggests) that is reduced to PE12. ROCE of 21% and operating margin of 21% suggesting the company has economic moat from know-how and patents. There is also a 3.5% div yield and dividend cover of 2. Five years of increasing and positive Net Asset Value per Share. 3 years of increasing profits. What is not to like!
Now the extra 410M shares are added to the 28.77m shares present. A 2.625p share price equates to grossly overvalued 12M market cap. There is only 5M cash in this shell. I think the share price will decrease to fair value (5M market cap) at 1.2p in January. The shares will be suspended on 20th of January as 1 year will have passed as a investment company.
MOnzur, No you will not be paid for the shares you will end up with a unlisted shareholding. Which you will not be able to dispose of easily and if you do it will be a large discount. Better to sell before the delisting!
Hi badeli, Not sure what the ADVFN email reply was on about suspension was today after all. Lets hope the reverse acquisition goes through. It has been a long wait. Merry Christmas to all
Serendipity, If the reverse acquisition is successful it will be a very nice investment. However, there are risks here so I would not have to large a position compared to your overall portfolio.